FibroGen Appoints Thane Wettig as Chief Commercial Officer
June 22 2020 - 7:00AM
FibroGen, Inc. (NASDAQ: FGEN) announced the appointment of Thane
Wettig to the newly-created position of Chief Commercial Officer,
where he will lead FibroGen’s commercialization efforts, leveraging
more than 30 years of global biopharmaceutical leadership and
experience.
“I am excited to welcome Thane to FibroGen as our new Chief
Commercial Officer,” said Enrique Conterno, Chief Executive
Officer, FibroGen. “Thane’s expertise, experience and track-record
for results make him the ideal person to lead FibroGen’s commercial
operations. I look forward to his leadership impact in working with
our partners to ensure roxadustat’s commercial success and to
realize the potential of pamrevlumab across several high-value
indications.”
Mr. Wettig most recently served as Chief Commercial Officer and
Metabolic Franchise Head at Intarcia Therapeutics. Prior to joining
Intarcia in 2018, Thane spent more than 27 years at Lilly in roles
of increasing responsibility, where he served as Vice President of
Global Marketing, Strategy and Alliance Management for Lilly
Diabetes, leading the development and launch of multiple
blockbuster diabetes medicines during a period of unprecedented
growth of Lilly’s diabetes business. Thane also played an integral
role in the design and management of Lilly’s highly successful
diabetes alliance.
Thane began his career at Lilly in sales, had additional
experiences in business development, sales operations, marketing –
U.S. and Global, before serving as Vice President of Global
Marketing for Lilly Diabetes. He is recognized throughout the
industry as a seasoned executive with extensive launch experience.
Mr. Wettig received his M.B.A. and B.A. in biology from Washington
University in St. Louis.
“I’m thrilled to be joining FibroGen at such an exciting time
for the company and I’m looking forward to working closely with our
partners, AstraZeneca and Astellas, to ensure roxadustat can reach
as many chronic kidney disease patients with anemia as possible on
a worldwide basis,” said Thane Wettig, Chief Commercial Officer,
FibroGen. “In addition, I look forward to building and leading the
commercial organization as we accelerate brand development and,
ultimately, global commercialization activities for pamrevlumab. I
am excited to once again be working with Enrique, as well as the
entire FibroGen team.”
About FibroGenFibroGen, Inc. is a
biopharmaceutical company committed to discovering, developing and
commercializing a pipeline of first-in-class therapeutics. The
company applies its pioneering expertise in hypoxia-inducible
factor (HIF) and connective tissue growth factor (CTGF) biology to
advance innovative medicines to treat unmet needs. The Company is
currently developing and commercializing roxadustat, an oral small
molecule inhibitor of HIF prolyl hydroxylase activity, for anemia
associated with chronic kidney disease (CKD). Roxadustat is also in
clinical development for anemia associated with myelodysplastic
syndromes (MDS) and for chemotherapy-induced anemia. Pamrevlumab,
an anti-CTGF human monoclonal antibody, is in clinical development
for the treatment of idiopathic pulmonary fibrosis (IPF), locally
advanced unresectable pancreatic cancer, Duchenne muscular
dystrophy (DMD), and coronavirus (COVID-19). For more information,
please visit www.fibrogen.com.
Forward-Looking StatementsThis release contains
forward-looking statements regarding our strategy, future plans and
prospects, including statements regarding the development and
commercialization of the company’s product candidates. These
forward-looking statements include, but are not limited to,
statements about our plans, objectives, representations and
contentions and are not historical facts and typically are
identified by use of terms such as “may,” “will”, “should,” “on
track,” “could,” “expect,” “plan,” “anticipate,” “believe,”
“estimate,” “predict,” “potential,” “continue” and similar words,
although some forward-looking statements are expressed differently.
Our actual results may differ materially from those indicated in
these forward-looking statements due to risks and uncertainties
related to the continued progress and timing of our various
programs, including the enrollment and results from ongoing and
potential future clinical trials, and other matters that are
described in our Annual Report on Form 10-K for the fiscal year
ended December 31, 2019 and our Quarterly Report on Form 10-Q for
quarter ended March 31, 2020 filed with the Securities and Exchange
Commission (SEC), including the risk factors set forth therein.
Investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
release, and we undertake no obligation to update any
forward-looking statement in this press release, except as required
by law.
Contact:FibroGen, Inc.
Media Inquiries:Sara
Iacovino1.703.474.4452sara.iacovino@gcihealth.com
Investors:Michael Tung, M.D.Corporate Strategy / Investor
Relations 1.415.978.1434mtung@fibrogen.com
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024